Dr. Reddy’s Q4 hit by lower Revlimid; analysts warn of two key risks

Despite the weak quarter, management maintained its outlook of achieving double-digit revenue growth along with margins of around 25%.

Leave a Reply

Your email address will not be published. Required fields are marked *